Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | Clinical value of event-free survival in AML

Jorge Cortes • 17 Jun 2020
ESH AL 2020
Acute Myeloid Leukemia Leukemia Antibodies Gemtuzumab ozogamicin

Jorge Cortes, MD, Georgia Cancer Center, Augusta University, Augusta, GA, discusses the clinical value of event-free survival (EFS) in acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jorge Cortes

2:12
Key emerging trials in CML and the importance of improving treatment-free remission rates
Jorge Cortes • 7 Sep 2023
2:09
Social determinants of health & their impact on patients with hematological malignancies
Jorge Cortes • 7 Sep 2023
1:57
Post-hoc analysis of OPTIC: patient responses to ponatinib by T315I mutational status
Jorge Cortes • 7 Sep 2023
2:21
Exciting updates in the field of CML: disease pathophysiology & novel agents
Jorge Cortes • 7 Sep 2023

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals